23andMe At ASHG 2017

The annual meeting of the American Society of Human Genetics kicks off in Orlando this October packed with five days of seminars, panel discussions, talks, and presentations that are all part of an event that might best be described as the Coachella (or Woodstock if you prefer) of genetics.

This year the main event, called the “Presidential Symposium,” will be a hosted conversation on global health issues with Microsoft co-founder Bill Gates, who now co-chairs the Bill & Melinda Gates Foundation, and Francis Collins, the director of the National Institutes of Health.

But highlighting just one of the hundreds of talks during the week risks breezing past dozens of equally arresting subjects that will be part of this yearly event — gene editing, genetic education and a slew of new genetic research.

Like in past years, 23andMe’s research team and its research will be well represented, but we’ll also be hosting a workshop about our research collaborations and live-tweeting from the meeting, and we have a few fun surprises while we’re in Orlando.

Here is a list of 23andMe’s involvement at ASHG:

 

Educational Event

 

GWAS and Beyond: Academic Collaborations with 23andMe
 

    Adam Auton

  • Adam Auton, D.Phil. (23andMe): Introduction to 23andMe research and collaborations
  • John Perry, Ph.D. (University of Cambridge): Using population genetics to understand the aetiology of reproductive health and biological ageing
  • Alice S. Whittemore, Ph.D. and Nilah Monnier Ioannidis, Ph.D. (Stanford University): Collaborations with 23andMe on the genetic basis of cutaneous squamous cell cancer (cSCC)
  • Time: Oct. 18, 12:30 pm – 1:45 pm
  • Location: Lake Eola – Lobby Level/Hilton Orlando Hotel

 

Talks


Large-scale identity-by-descent mapping discovers rare haplotypes of large effect

 

    Suyash Shringapure

  • Presenter: Suyash Shringarpure, Ph.D., Senior Statistical Geneticist
  • Author(s): S. Shringarpure; D. Hinds; V. Vacic; 23andMe Research Team
  • Time: Oct. 19, 10:15 am – 10:30 am
  • Location: Room 330A – Level 3/Convention Center

 
 

GWAS of canker sores implicates Th-1 pathway and shared genetic architecture with immune-mediated disease

 

    Fah Sathirapongsasuti

  • Presenter: Fah Sathirapongsasuti, Ph.D., Senior Computational Biologist
  • Author(s): F. Sathirapongsasuti; S. Pitts; D. Hinds; V. Vacic; R. Gentleman; the 23andMe Research Team
  • Time: Oct. 19, 11:45 am – 12 pm
  • Location: Room 220F – Level2/Convention Center

 

Posters

 

All posters can be found in the Exhibit Hall on Level 1 of the Convention Center.
 

Tipping the scales: Participants make healthy dietary changes in response to direct-to-consumer genetic test results
 

    Sarah Laskey

  • Presenter: Sarah Laskey, Ph.D., Health R&D Scientist
  • Author(s): S.B. Laskey; J.F. Shelton; M. Johnson; C. Wilson; R. Smith; B.L. Koelsch; The 23andMe Research Team
  • Time: Oct. 18, 3pm – 4 pm

 
 
 

Clonal Hematopoiesis: genetic and phenotypic associations in the general population
 

    Chao Tian

  • Presenter: Chao Tian, Ph.D., Senior Statistical Geneticist
  • Author(s): C. Tian; P. Fontanillas; J. Tung; D. Hinds; the 23andMe Research Team
  • Time: Oct. 18, 3 pm – 4 pm

 


Minds, genes, and machines: Performance on online cognitive assessments is correlated with individual characteristics in 23andMe customers

 

    Olga Sazonova

  • Presenter: Olga Sazonova, Ph.D., Senior Computational Biologist
  • Author(s): O.V. Sazonova; L. Germine; C. Wilson; P. Fontanillas; C.E. Carey; 23andMe Research Team
  • Time: Oct. 19, 2 pm – 3 pm

 

 

A web-based initiative to accelerate research on African ancestry in the Americas

 

    Meghan Moreno

  • Presenter: Meghan Moreno, Ph.D., Product Manager
  • Author(s): M.E. Moreno; K. Bryc; P.K. Penton; R. Rubenstein; L. Vermillion; J.L. Mountain; the 23andMe Research Team

  • Time: Oct. 20, 12:30 pm – 1:30 pm

 


Human knockouts in the Ashkenazi Jewish population

 

    Aaron Kleinman

  • Presenter: Aaron Kleinman, Ph.D., Senior Computational Biologist
  • Author(s): A. Kleinman; O. Sazonova; S. Pitts; V. Vacic; R. Gentleman; the 23andMe Research Team
  • Time: Oct. 20, 12:30 pm – 1:30 pm

* The 23andMe PGS test includes health predisposition and carrier status reports. Health predisposition reports include both reports that meet FDA requirements for genetic health risks and reports which are based on 23andMe research and have not been reviewed by the FDA. The test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks and reporting carrier status. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person's overall risk of developing the disease. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. Our carrier status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future, the health of your fetus, or your newborn child's risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk. Warnings & Limitations: The 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) is indicated for reporting of 44 variants in the BRCA1 and BRCA2 genes. The report describes if a person's genetic result is associated with an increased risk of developing breast cancer and ovarian cancer and may be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers. The variants included in this report do not represent the majority of the BRCA1/BRCA2 variants in people of most ethnicities. This report does not include variants in other genes linked to hereditary cancers and the absence of variants included in this report does not rule out the presence of other genetic variants that may impact cancer risk. This report is for over-the-counter use by adults over the age of 18, and provides genetic information to inform discussions with a healthcare professional. The PGS test is not a substitute for visits to a healthcare professional for recommended screenings or appropriate follow-up. Results should be confirmed in a clinical setting before taking any medical action. For important information and limitations regarding each genetic health risk and carrier status report, visit 23andme.com/test-info/

**23andMe PGS Pharmacogenetics reports: The 23andMe test uses qualitative genotyping to detect 3 variants in the CYP2C19 gene, 2 variants in the DPYD gene and 1 variant in the SLCO1B1 gene in the genomic DNA of adults from saliva for the purpose of reporting and interpreting information about the processing of certain therapeutics to inform discussions with a healthcare professional. It does not describe if a person will or will not respond to a particular therapeutic. Our CYP2C19 Pharmacogenetics report provides certain information about variants associated with metabolism of some therapeutics and provides interpretive drug information regarding the potential effect of citalopram and clopidogrel therapy. Our SLCO1B1 Pharmacogenetics report provides certain information about variants associated with the processing of some therapeutics and provides interpretive drug information regarding the potential effect of simvastatin therapy. Our DPYD Pharmacogenetics report does not describe the association between detected variants and any specific therapeutic. Results for DPYD and certain CYP2C19 results should be confirmed by an independent genetic test prescribed by your own healthcare provider before taking any medical action. Warning: Test information should not be used to start, stop, or change any course of treatment and does not test for all possible variants that may affect metabolism or protein function. The PGS test is not a substitute for visits to a healthcare professional. Making changes to your current regimen can lead to harmful side effects or reduced intended benefits of your medication, therefore consult with your healthcare professional before taking any medical action. For important information and limitations regarding Pharmacogenetic reports, visit 23andme.com/test-info/pharmacogenetics/